nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—atopic dermatitis—psoriasis	0.593	1	CtDrD
Pimecrolimus—FKBP1A—Cyclosporine—psoriasis	0.176	0.696	CbGbCtD
Pimecrolimus—CYP3A4—Calcitriol—psoriasis	0.0147	0.0582	CbGbCtD
Pimecrolimus—CYP3A4—Methoxsalen—psoriasis	0.0114	0.0453	CbGbCtD
Pimecrolimus—CYP3A4—Cholecalciferol—psoriasis	0.00758	0.03	CbGbCtD
Pimecrolimus—CYP3A4—Mycophenolate mofetil—psoriasis	0.00657	0.026	CbGbCtD
Pimecrolimus—CYP3A4—Triamcinolone—psoriasis	0.00657	0.026	CbGbCtD
Pimecrolimus—CYP3A4—Betamethasone—psoriasis	0.00564	0.0223	CbGbCtD
Pimecrolimus—CYP3A4—Prednisolone—psoriasis	0.00556	0.022	CbGbCtD
Pimecrolimus—CYP3A4—Hydrocortisone—psoriasis	0.00527	0.0209	CbGbCtD
Pimecrolimus—CYP3A4—Prednisone—psoriasis	0.00525	0.0208	CbGbCtD
Pimecrolimus—CYP3A4—Cyclosporine—psoriasis	0.00498	0.0197	CbGbCtD
Pimecrolimus—CYP3A4—Dexamethasone—psoriasis	0.00328	0.013	CbGbCtD
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—STAT3—psoriasis	0.000122	0.00471	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—NFKB1—psoriasis	0.000122	0.0047	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—TYK2—psoriasis	0.000121	0.00465	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IFNG—psoriasis	0.000121	0.00464	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—PCNA—psoriasis	0.00012	0.0046	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—STAT3—psoriasis	0.000118	0.00453	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD4—psoriasis	0.000117	0.00448	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—CXCL8—psoriasis	0.000116	0.00447	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—SOCS1—psoriasis	0.000115	0.00444	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HLA-E—psoriasis	0.000115	0.00444	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—JUN—psoriasis	0.000113	0.00437	CbGpPWpGaD
Pimecrolimus—MTOR—RANKL/RANK Signaling Pathway—JUN—psoriasis	0.000112	0.0043	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000111	0.00426	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—STAT3—psoriasis	0.00011	0.00422	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—IFNG—psoriasis	0.000109	0.0042	CbGpPWpGaD
Pimecrolimus—MTOR—RANKL/RANK Signaling Pathway—NFKB1—psoriasis	0.000108	0.00414	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—NFKB1—psoriasis	0.000108	0.00414	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KIR2DS1—psoriasis	0.000107	0.00411	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—CD4—psoriasis	0.000105	0.00406	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—SOCS1—psoriasis	0.000104	0.00402	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—NFKB1—psoriasis	0.0001	0.00386	CbGpPWpGaD
Pimecrolimus—MTOR—Interferon type I signaling pathways—STAT3—psoriasis	9.81e-05	0.00378	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—TYK2—psoriasis	9.75e-05	0.00375	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—JUN—psoriasis	9.66e-05	0.00372	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—TYK2—psoriasis	9.48e-05	0.00365	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—JUN—psoriasis	9.43e-05	0.00363	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—NFKB1—psoriasis	9.42e-05	0.00362	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—TYK2—psoriasis	9.4e-05	0.00362	CbGpPWpGaD
Pimecrolimus—MTOR—CDC42 signaling events—JUN—psoriasis	9.22e-05	0.00355	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—TYK2—psoriasis	9.15e-05	0.00352	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—TYK2—psoriasis	9.15e-05	0.00352	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—NFKB1—psoriasis	9.08e-05	0.00349	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ERAP1—psoriasis	9.02e-05	0.00347	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—STAT3—psoriasis	9.02e-05	0.00347	CbGpPWpGaD
Pimecrolimus—MTOR—LKB1 signaling events—TP53—psoriasis	8.99e-05	0.00346	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CD4—psoriasis	8.9e-05	0.00343	CbGpPWpGaD
Pimecrolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.81e-05	0.00339	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HCAR2—psoriasis	8.76e-05	0.00337	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—VEGFA—psoriasis	8.55e-05	0.00329	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—STAT3—psoriasis	8.46e-05	0.00326	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—PCNA—psoriasis	8.46e-05	0.00325	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—NFKB1—psoriasis	8.4e-05	0.00323	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—TNF—psoriasis	8.37e-05	0.00322	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—STAT3—psoriasis	8.36e-05	0.00322	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—JUN—psoriasis	8.28e-05	0.00319	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—DDX58—psoriasis	8.27e-05	0.00318	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.26e-05	0.00318	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HLA-B—psoriasis	8.21e-05	0.00316	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.15e-05	0.00314	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—TYK2—psoriasis	8.11e-05	0.00312	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TNF—psoriasis	8.08e-05	0.00311	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—NFKBIA—psoriasis	7.81e-05	0.003	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—psoriasis	7.71e-05	0.00297	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—NFKB1—psoriasis	7.67e-05	0.00295	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—IL6—psoriasis	7.66e-05	0.00295	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—TYK2—psoriasis	7.66e-05	0.00295	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—TYK2—psoriasis	7.6e-05	0.00293	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TAGAP—psoriasis	7.59e-05	0.00292	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—STAT3—psoriasis	7.55e-05	0.0029	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—TP53—psoriasis	7.49e-05	0.00288	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	7.34e-05	0.00283	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—CXCL8—psoriasis	7.17e-05	0.00276	CbGpPWpGaD
Pimecrolimus—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.13e-05	0.00274	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TP53—psoriasis	7.13e-05	0.00274	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	7.07e-05	0.00272	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NFKBIA—psoriasis	6.94e-05	0.00267	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—STAT3—psoriasis	6.89e-05	0.00265	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—STAT3—psoriasis	6.89e-05	0.00265	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—JUN—psoriasis	6.66e-05	0.00256	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—JUN—psoriasis	6.66e-05	0.00256	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CAT—psoriasis	6.64e-05	0.00256	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NFKBIA—psoriasis	6.62e-05	0.00255	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL6—psoriasis	6.52e-05	0.00251	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—TYK2—psoriasis	6.5e-05	0.0025	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—psoriasis	6.46e-05	0.00248	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	6.41e-05	0.00247	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—TYK2—psoriasis	6.22e-05	0.00239	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—TP53—psoriasis	6.16e-05	0.00237	CbGpPWpGaD
Pimecrolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.14e-05	0.00236	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—NFKBIA—psoriasis	6.13e-05	0.00236	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—TYK2—psoriasis	6.12e-05	0.00236	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ITGAL—psoriasis	6.02e-05	0.00232	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriasis	5.97e-05	0.0023	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—TYK2—psoriasis	5.85e-05	0.00225	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—TYK2—psoriasis	5.82e-05	0.00224	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—TYK2—psoriasis	5.79e-05	0.00223	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—STAT3—psoriasis	5.77e-05	0.00222	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—TYK2—psoriasis	5.76e-05	0.00222	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—psoriasis	5.74e-05	0.00221	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IFIH1—psoriasis	5.69e-05	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—REL—psoriasis	5.63e-05	0.00217	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	5.5e-05	0.00212	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERAP1—psoriasis	5.47e-05	0.00211	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—TYK2—psoriasis	5.42e-05	0.00209	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—TYK2—psoriasis	5.42e-05	0.00209	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—TYK2—psoriasis	5.42e-05	0.00209	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—VEGFA—psoriasis	5.41e-05	0.00208	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HLA-C—psoriasis	5.4e-05	0.00208	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—TYK2—psoriasis	5.37e-05	0.00207	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TNFAIP3—psoriasis	5.33e-05	0.00205	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—TYK2—psoriasis	5.33e-05	0.00205	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—TYK2—psoriasis	5.3e-05	0.00204	CbGpPWpGaD
Pimecrolimus—Back pain—Mycophenolate mofetil—psoriasis	5.3e-05	0.000413	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-C—psoriasis	5.18e-05	0.00199	CbGpPWpGaD
Pimecrolimus—Immune system disorder—Hydrocortisone—psoriasis	5.18e-05	0.000403	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—JUN—psoriasis	5.18e-05	0.00199	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	5.16e-05	0.000402	CcSEcCtD
Pimecrolimus—Angioedema—Cyclosporine—psoriasis	5.13e-05	0.0004	CcSEcCtD
Pimecrolimus—Nausea—Acitretin—psoriasis	5.12e-05	0.000399	CcSEcCtD
Pimecrolimus—Erythema—Prednisolone—psoriasis	5.11e-05	0.000398	CcSEcCtD
Pimecrolimus—Nausea—Fluocinolone Acetonide—psoriasis	5.1e-05	0.000397	CcSEcCtD
Pimecrolimus—Paraesthesia—Mycophenolic acid—psoriasis	5.09e-05	0.000396	CcSEcCtD
Pimecrolimus—Dyspnoea—Mycophenolic acid—psoriasis	5.05e-05	0.000393	CcSEcCtD
Pimecrolimus—Angioedema—Mycophenolate mofetil—psoriasis	5.01e-05	0.00039	CcSEcCtD
Pimecrolimus—Malnutrition—Hydrocortisone—psoriasis	4.99e-05	0.000389	CcSEcCtD
Pimecrolimus—Erythema—Hydrocortisone—psoriasis	4.99e-05	0.000389	CcSEcCtD
Pimecrolimus—Hypersensitivity—Hydroxyurea—psoriasis	4.98e-05	0.000388	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—JUN—psoriasis	4.98e-05	0.00192	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—NFKB1—psoriasis	4.98e-05	0.00192	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HCAR2—psoriasis	4.92e-05	0.0019	CbGpPWpGaD
Pimecrolimus—Cough—Cyclosporine—psoriasis	4.9e-05	0.000382	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Mycophenolic acid—psoriasis	4.89e-05	0.000381	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.85e-05	0.00187	CbGpPWpGaD
Pimecrolimus—Constipation—Mycophenolic acid—psoriasis	4.85e-05	0.000377	CcSEcCtD
Pimecrolimus—Pain—Mycophenolic acid—psoriasis	4.85e-05	0.000377	CcSEcCtD
Pimecrolimus—MTOR—Immune System—DDX58—psoriasis	4.82e-05	0.00185	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	4.8e-05	0.00185	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	4.8e-05	0.00185	CbGpPWpGaD
Pimecrolimus—Arthralgia—Cyclosporine—psoriasis	4.78e-05	0.000372	CcSEcCtD
Pimecrolimus—Cough—Mycophenolate mofetil—psoriasis	4.78e-05	0.000372	CcSEcCtD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—psoriasis	4.77e-05	0.00184	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—JUN—psoriasis	4.76e-05	0.00183	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	4.75e-05	0.00037	CcSEcCtD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—JUN—psoriasis	4.71e-05	0.00181	CbGpPWpGaD
Pimecrolimus—Erythema—Triamcinolone—psoriasis	4.7e-05	0.000366	CcSEcCtD
Pimecrolimus—Angioedema—Prednisolone—psoriasis	4.67e-05	0.000364	CcSEcCtD
Pimecrolimus—Arthralgia—Mycophenolate mofetil—psoriasis	4.66e-05	0.000363	CcSEcCtD
Pimecrolimus—Breast disorder—Methotrexate—psoriasis	4.66e-05	0.000363	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events—IL6—psoriasis	4.64e-05	0.00178	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Mycophenolic acid—psoriasis	4.63e-05	0.000361	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	4.63e-05	0.000361	CcSEcCtD
Pimecrolimus—Diarrhoea—Hydroxyurea—psoriasis	4.63e-05	0.00036	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—psoriasis	4.6e-05	0.00177	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Cyclosporine—psoriasis	4.58e-05	0.000357	CcSEcCtD
Pimecrolimus—Oedema—Cyclosporine—psoriasis	4.58e-05	0.000357	CcSEcCtD
Pimecrolimus—Eye disorder—Dexamethasone—psoriasis	4.58e-05	0.000357	CcSEcCtD
Pimecrolimus—Eye disorder—Betamethasone—psoriasis	4.58e-05	0.000357	CcSEcCtD
Pimecrolimus—Angioedema—Hydrocortisone—psoriasis	4.56e-05	0.000355	CcSEcCtD
Pimecrolimus—Infection—Cyclosporine—psoriasis	4.55e-05	0.000355	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—STAT3—psoriasis	4.55e-05	0.00175	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL20—psoriasis	4.55e-05	0.00175	CbGpPWpGaD
Pimecrolimus—Back pain—Triamcinolone—psoriasis	4.55e-05	0.000354	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—NFKBIA—psoriasis	4.51e-05	0.00174	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Cyclosporine—psoriasis	4.5e-05	0.00035	CcSEcCtD
Pimecrolimus—Abdominal pain—Mycophenolic acid—psoriasis	4.48e-05	0.000349	CcSEcCtD
Pimecrolimus—Body temperature increased—Mycophenolic acid—psoriasis	4.48e-05	0.000349	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—HLA-E—psoriasis	4.48e-05	0.00172	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—STAT3—psoriasis	4.48e-05	0.00172	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—psoriasis	4.48e-05	0.00172	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—psoriasis	4.48e-05	0.00172	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Mycophenolate mofetil—psoriasis	4.47e-05	0.000348	CcSEcCtD
Pimecrolimus—Oedema—Mycophenolate mofetil—psoriasis	4.47e-05	0.000348	CcSEcCtD
Pimecrolimus—Asthma—Methotrexate—psoriasis	4.45e-05	0.000347	CcSEcCtD
Pimecrolimus—Skin disorder—Cyclosporine—psoriasis	4.45e-05	0.000347	CcSEcCtD
Pimecrolimus—Infection—Mycophenolate mofetil—psoriasis	4.44e-05	0.000346	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—psoriasis	4.43e-05	0.0017	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—psoriasis	4.4e-05	0.00169	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	4.39e-05	0.00169	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Mycophenolate mofetil—psoriasis	4.39e-05	0.000342	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	4.35e-05	0.00168	CbGpPWpGaD
Pimecrolimus—Skin disorder—Mycophenolate mofetil—psoriasis	4.34e-05	0.000338	CcSEcCtD
Pimecrolimus—Vomiting—Hydroxyurea—psoriasis	4.3e-05	0.000335	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-E—psoriasis	4.3e-05	0.00165	CbGpPWpGaD
Pimecrolimus—Angioedema—Triamcinolone—psoriasis	4.29e-05	0.000334	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—TAGAP—psoriasis	4.27e-05	0.00164	CbGpPWpGaD
Pimecrolimus—Rash—Hydroxyurea—psoriasis	4.27e-05	0.000332	CcSEcCtD
Pimecrolimus—Erythema—Dexamethasone—psoriasis	4.26e-05	0.000332	CcSEcCtD
Pimecrolimus—Erythema—Betamethasone—psoriasis	4.26e-05	0.000332	CcSEcCtD
Pimecrolimus—Dermatitis—Hydroxyurea—psoriasis	4.26e-05	0.000332	CcSEcCtD
Pimecrolimus—Headache—Hydroxyurea—psoriasis	4.24e-05	0.00033	CcSEcCtD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	4.22e-05	0.00163	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	4.22e-05	0.000329	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Cyclosporine—psoriasis	4.18e-05	0.000325	CcSEcCtD
Pimecrolimus—Oedema—Prednisolone—psoriasis	4.17e-05	0.000325	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Prednisolone—psoriasis	4.17e-05	0.000325	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Methotrexate—psoriasis	4.14e-05	0.000322	CcSEcCtD
Pimecrolimus—Paraesthesia—Cyclosporine—psoriasis	4.12e-05	0.000321	CcSEcCtD
Pimecrolimus—Cough—Triamcinolone—psoriasis	4.1e-05	0.000319	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—STAT3—psoriasis	4.1e-05	0.00158	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Cyclosporine—psoriasis	4.09e-05	0.000318	CcSEcCtD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—psoriasis	4.08e-05	0.00157	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	4.07e-05	0.000317	CcSEcCtD
Pimecrolimus—Oedema—Hydrocortisone—psoriasis	4.07e-05	0.000317	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Hydrocortisone—psoriasis	4.07e-05	0.000317	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Methotrexate—psoriasis	4.07e-05	0.000317	CcSEcCtD
Pimecrolimus—Infection—Hydrocortisone—psoriasis	4.05e-05	0.000315	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—psoriasis	4.03e-05	0.00155	CbGpPWpGaD
Pimecrolimus—Nausea—Hydroxyurea—psoriasis	4.02e-05	0.000313	CcSEcCtD
Pimecrolimus—Paraesthesia—Mycophenolate mofetil—psoriasis	4.02e-05	0.000313	CcSEcCtD
Pimecrolimus—Pruritus—Mycophenolic acid—psoriasis	4.01e-05	0.000312	CcSEcCtD
Pimecrolimus—Nervous system disorder—Hydrocortisone—psoriasis	4e-05	0.000311	CcSEcCtD
Pimecrolimus—Pneumonia—Methotrexate—psoriasis	4e-05	0.000311	CcSEcCtD
Pimecrolimus—Eye disorder—Prednisone—psoriasis	3.99e-05	0.000311	CcSEcCtD
Pimecrolimus—Dyspnoea—Mycophenolate mofetil—psoriasis	3.99e-05	0.00031	CcSEcCtD
Pimecrolimus—Infestation NOS—Methotrexate—psoriasis	3.97e-05	0.000309	CcSEcCtD
Pimecrolimus—Infestation—Methotrexate—psoriasis	3.97e-05	0.000309	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—psoriasis	3.97e-05	0.00153	CbGpPWpGaD
Pimecrolimus—Flushing—Prednisone—psoriasis	3.96e-05	0.000308	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Cyclosporine—psoriasis	3.96e-05	0.000308	CcSEcCtD
Pimecrolimus—Skin disorder—Hydrocortisone—psoriasis	3.96e-05	0.000308	CcSEcCtD
Pimecrolimus—Constipation—Cyclosporine—psoriasis	3.92e-05	0.000305	CcSEcCtD
Pimecrolimus—Pain—Cyclosporine—psoriasis	3.92e-05	0.000305	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—NFKB1—psoriasis	3.91e-05	0.0015	CbGpPWpGaD
Pimecrolimus—Angioedema—Dexamethasone—psoriasis	3.9e-05	0.000303	CcSEcCtD
Pimecrolimus—Angioedema—Betamethasone—psoriasis	3.9e-05	0.000303	CcSEcCtD
Pimecrolimus—Diarrhoea—Mycophenolic acid—psoriasis	3.88e-05	0.000302	CcSEcCtD
Pimecrolimus—Conjunctivitis—Methotrexate—psoriasis	3.86e-05	0.000301	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	3.86e-05	0.000301	CcSEcCtD
Pimecrolimus—Immune system disorder—Prednisone—psoriasis	3.85e-05	0.0003	CcSEcCtD
Pimecrolimus—Oedema—Triamcinolone—psoriasis	3.84e-05	0.000299	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Triamcinolone—psoriasis	3.84e-05	0.000299	CcSEcCtD
Pimecrolimus—Pain—Mycophenolate mofetil—psoriasis	3.82e-05	0.000298	CcSEcCtD
Pimecrolimus—Constipation—Mycophenolate mofetil—psoriasis	3.82e-05	0.000298	CcSEcCtD
Pimecrolimus—Infection—Triamcinolone—psoriasis	3.81e-05	0.000297	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR in disease—STAT3—psoriasis	3.8e-05	0.00146	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Cyclosporine—psoriasis	3.75e-05	0.000292	CcSEcCtD
Pimecrolimus—Epistaxis—Methotrexate—psoriasis	3.75e-05	0.000292	CcSEcCtD
Pimecrolimus—Paraesthesia—Prednisolone—psoriasis	3.75e-05	0.000292	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—psoriasis	3.74e-05	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—SOCS1—psoriasis	3.74e-05	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—psoriasis	3.72e-05	0.00143	CbGpPWpGaD
Pimecrolimus—Malnutrition—Prednisone—psoriasis	3.71e-05	0.000289	CcSEcCtD
Pimecrolimus—Erythema—Prednisone—psoriasis	3.71e-05	0.000289	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—STAT3—psoriasis	3.71e-05	0.00143	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Hydrocortisone—psoriasis	3.71e-05	0.000289	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—TYK2—psoriasis	3.69e-05	0.00142	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Hydrocortisone—psoriasis	3.66e-05	0.000285	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	3.66e-05	0.000285	CcSEcCtD
Pimecrolimus—MTOR—Immune System—ITGAL—psoriasis	3.65e-05	0.00141	CbGpPWpGaD
Pimecrolimus—Urticaria—Cyclosporine—psoriasis	3.64e-05	0.000284	CcSEcCtD
Pimecrolimus—Body temperature increased—Cyclosporine—psoriasis	3.62e-05	0.000282	CcSEcCtD
Pimecrolimus—Abdominal pain—Cyclosporine—psoriasis	3.62e-05	0.000282	CcSEcCtD
Pimecrolimus—Vomiting—Mycophenolic acid—psoriasis	3.6e-05	0.000281	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—SOCS1—psoriasis	3.59e-05	0.00138	CbGpPWpGaD
Pimecrolimus—Rash—Mycophenolic acid—psoriasis	3.57e-05	0.000278	CcSEcCtD
Pimecrolimus—Dermatitis—Mycophenolic acid—psoriasis	3.57e-05	0.000278	CcSEcCtD
Pimecrolimus—Pain—Prednisolone—psoriasis	3.57e-05	0.000278	CcSEcCtD
Pimecrolimus—Urticaria—Mycophenolate mofetil—psoriasis	3.55e-05	0.000277	CcSEcCtD
Pimecrolimus—Headache—Mycophenolic acid—psoriasis	3.55e-05	0.000276	CcSEcCtD
Pimecrolimus—Pharyngitis—Methotrexate—psoriasis	3.54e-05	0.000276	CcSEcCtD
Pimecrolimus—Body temperature increased—Mycophenolate mofetil—psoriasis	3.54e-05	0.000275	CcSEcCtD
Pimecrolimus—Abdominal pain—Mycophenolate mofetil—psoriasis	3.54e-05	0.000275	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Hydrocortisone—psoriasis	3.52e-05	0.000274	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Triamcinolone—psoriasis	3.49e-05	0.000272	CcSEcCtD
Pimecrolimus—Pain—Hydrocortisone—psoriasis	3.48e-05	0.000271	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Betamethasone—psoriasis	3.48e-05	0.000271	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Dexamethasone—psoriasis	3.48e-05	0.000271	CcSEcCtD
Pimecrolimus—Oedema—Betamethasone—psoriasis	3.48e-05	0.000271	CcSEcCtD
Pimecrolimus—Oedema—Dexamethasone—psoriasis	3.48e-05	0.000271	CcSEcCtD
Pimecrolimus—Infection—Dexamethasone—psoriasis	3.46e-05	0.000269	CcSEcCtD
Pimecrolimus—Infection—Betamethasone—psoriasis	3.46e-05	0.000269	CcSEcCtD
Pimecrolimus—Paraesthesia—Triamcinolone—psoriasis	3.44e-05	0.000268	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—CXCL8—psoriasis	3.43e-05	0.00132	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Triamcinolone—psoriasis	3.42e-05	0.000266	CcSEcCtD
Pimecrolimus—MTOR—Immune System—REL—psoriasis	3.42e-05	0.00131	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Betamethasone—psoriasis	3.41e-05	0.000266	CcSEcCtD
Pimecrolimus—Nervous system disorder—Dexamethasone—psoriasis	3.41e-05	0.000266	CcSEcCtD
Pimecrolimus—Angioedema—Prednisone—psoriasis	3.39e-05	0.000264	CcSEcCtD
Pimecrolimus—Hypersensitivity—Cyclosporine—psoriasis	3.38e-05	0.000263	CcSEcCtD
Pimecrolimus—Nausea—Mycophenolic acid—psoriasis	3.37e-05	0.000262	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	3.36e-05	0.00129	CbGpPWpGaD
Pimecrolimus—Eye disorder—Methotrexate—psoriasis	3.33e-05	0.00026	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Hydrocortisone—psoriasis	3.33e-05	0.000259	CcSEcCtD
Pimecrolimus—MTOR—Immune System—IFIH1—psoriasis	3.32e-05	0.00128	CbGpPWpGaD
Pimecrolimus—Urticaria—Prednisolone—psoriasis	3.31e-05	0.000258	CcSEcCtD
Pimecrolimus—Hypersensitivity—Mycophenolate mofetil—psoriasis	3.29e-05	0.000257	CcSEcCtD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—psoriasis	3.29e-05	0.00127	CbGpPWpGaD
Pimecrolimus—Pain—Triamcinolone—psoriasis	3.28e-05	0.000255	CcSEcCtD
Pimecrolimus—Pruritus—Cyclosporine—psoriasis	3.24e-05	0.000253	CcSEcCtD
Pimecrolimus—Urticaria—Hydrocortisone—psoriasis	3.24e-05	0.000252	CcSEcCtD
Pimecrolimus—Immune system disorder—Methotrexate—psoriasis	3.22e-05	0.000251	CcSEcCtD
Pimecrolimus—Body temperature increased—Hydrocortisone—psoriasis	3.22e-05	0.000251	CcSEcCtD
Pimecrolimus—Abdominal pain—Hydrocortisone—psoriasis	3.22e-05	0.000251	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methotrexate—psoriasis	3.21e-05	0.00025	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—HLA-B—psoriasis	3.19e-05	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—JUN—psoriasis	3.19e-05	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD8A—psoriasis	3.19e-05	0.00123	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—psoriasis	3.18e-05	0.00122	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.17e-05	0.000247	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Betamethasone—psoriasis	3.17e-05	0.000247	CcSEcCtD
Pimecrolimus—Pruritus—Mycophenolate mofetil—psoriasis	3.16e-05	0.000246	CcSEcCtD
Pimecrolimus—Arthralgia—Prednisone—psoriasis	3.16e-05	0.000246	CcSEcCtD
Pimecrolimus—MTOR—Immune System—HLA-C—psoriasis	3.14e-05	0.00121	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	3.14e-05	0.000245	CcSEcCtD
Pimecrolimus—Diarrhoea—Cyclosporine—psoriasis	3.14e-05	0.000244	CcSEcCtD
Pimecrolimus—Paraesthesia—Dexamethasone—psoriasis	3.13e-05	0.000243	CcSEcCtD
Pimecrolimus—Paraesthesia—Betamethasone—psoriasis	3.13e-05	0.000243	CcSEcCtD
Pimecrolimus—MTOR—Immune System—TNFAIP3—psoriasis	3.1e-05	0.00119	CbGpPWpGaD
Pimecrolimus—Malnutrition—Methotrexate—psoriasis	3.1e-05	0.000242	CcSEcCtD
Pimecrolimus—Erythema—Methotrexate—psoriasis	3.1e-05	0.000242	CcSEcCtD
Pimecrolimus—Hypersensitivity—Prednisolone—psoriasis	3.07e-05	0.000239	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—NFKB1—psoriasis	3.07e-05	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-B—psoriasis	3.06e-05	0.00118	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Mycophenolate mofetil—psoriasis	3.06e-05	0.000238	CcSEcCtD
Pimecrolimus—Urticaria—Triamcinolone—psoriasis	3.05e-05	0.000237	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—psoriasis	3.04e-05	0.00117	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Triamcinolone—psoriasis	3.03e-05	0.000236	CcSEcCtD
Pimecrolimus—Oedema—Prednisone—psoriasis	3.03e-05	0.000236	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Prednisone—psoriasis	3.03e-05	0.000236	CcSEcCtD
Pimecrolimus—Infection—Prednisone—psoriasis	3.01e-05	0.000235	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Dexamethasone—psoriasis	3.01e-05	0.000234	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Betamethasone—psoriasis	3.01e-05	0.000234	CcSEcCtD
Pimecrolimus—Back pain—Methotrexate—psoriasis	3e-05	0.000234	CcSEcCtD
Pimecrolimus—Hypersensitivity—Hydrocortisone—psoriasis	3e-05	0.000234	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—psoriasis	3e-05	0.00115	CbGpPWpGaD
Pimecrolimus—Pain—Dexamethasone—psoriasis	2.98e-05	0.000232	CcSEcCtD
Pimecrolimus—Pain—Betamethasone—psoriasis	2.98e-05	0.000232	CcSEcCtD
Pimecrolimus—Nervous system disorder—Prednisone—psoriasis	2.97e-05	0.000231	CcSEcCtD
Pimecrolimus—Skin disorder—Prednisone—psoriasis	2.94e-05	0.000229	CcSEcCtD
Pimecrolimus—Vomiting—Cyclosporine—psoriasis	2.91e-05	0.000227	CcSEcCtD
Pimecrolimus—Rash—Cyclosporine—psoriasis	2.89e-05	0.000225	CcSEcCtD
Pimecrolimus—Dermatitis—Cyclosporine—psoriasis	2.89e-05	0.000225	CcSEcCtD
Pimecrolimus—Pruritus—Hydrocortisone—psoriasis	2.88e-05	0.000224	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—NFKB1—psoriasis	2.88e-05	0.00111	CbGpPWpGaD
Pimecrolimus—Headache—Cyclosporine—psoriasis	2.87e-05	0.000224	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—psoriasis	2.86e-05	0.0011	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—psoriasis	2.85e-05	0.0011	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Dexamethasone—psoriasis	2.85e-05	0.000222	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Betamethasone—psoriasis	2.85e-05	0.000222	CcSEcCtD
Pimecrolimus—Vomiting—Mycophenolate mofetil—psoriasis	2.84e-05	0.000221	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-A—psoriasis	2.84e-05	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—psoriasis	2.83e-05	0.00109	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HLA-A—psoriasis	2.83e-05	0.00109	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Triamcinolone—psoriasis	2.83e-05	0.00022	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—CRP—psoriasis	2.82e-05	0.00109	CbGpPWpGaD
Pimecrolimus—Rash—Mycophenolate mofetil—psoriasis	2.82e-05	0.00022	CcSEcCtD
Pimecrolimus—MTOR—DAP12 signaling—IL6—psoriasis	2.82e-05	0.00108	CbGpPWpGaD
Pimecrolimus—Dermatitis—Mycophenolate mofetil—psoriasis	2.82e-05	0.000219	CcSEcCtD
Pimecrolimus—Headache—Mycophenolate mofetil—psoriasis	2.8e-05	0.000218	CcSEcCtD
Pimecrolimus—Diarrhoea—Hydrocortisone—psoriasis	2.79e-05	0.000217	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—psoriasis	2.78e-05	0.00107	CbGpPWpGaD
Pimecrolimus—Urticaria—Betamethasone—psoriasis	2.77e-05	0.000215	CcSEcCtD
Pimecrolimus—Urticaria—Dexamethasone—psoriasis	2.77e-05	0.000215	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Prednisone—psoriasis	2.76e-05	0.000215	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—STAT3—psoriasis	2.76e-05	0.00106	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Betamethasone—psoriasis	2.75e-05	0.000214	CcSEcCtD
Pimecrolimus—Abdominal pain—Dexamethasone—psoriasis	2.75e-05	0.000214	CcSEcCtD
Pimecrolimus—Abdominal pain—Betamethasone—psoriasis	2.75e-05	0.000214	CcSEcCtD
Pimecrolimus—Body temperature increased—Dexamethasone—psoriasis	2.75e-05	0.000214	CcSEcCtD
Pimecrolimus—Nausea—Cyclosporine—psoriasis	2.72e-05	0.000212	CcSEcCtD
Pimecrolimus—Paraesthesia—Prednisone—psoriasis	2.72e-05	0.000212	CcSEcCtD
Pimecrolimus—Pruritus—Triamcinolone—psoriasis	2.71e-05	0.000211	CcSEcCtD
Pimecrolimus—Cough—Methotrexate—psoriasis	2.71e-05	0.000211	CcSEcCtD
Pimecrolimus—Nausea—Mycophenolate mofetil—psoriasis	2.66e-05	0.000207	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—psoriasis	2.65e-05	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—psoriasis	2.65e-05	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	2.65e-05	0.00102	CbGpPWpGaD
Pimecrolimus—Arthralgia—Methotrexate—psoriasis	2.64e-05	0.000206	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—APOE—psoriasis	2.64e-05	0.00102	CbGpPWpGaD
Pimecrolimus—Rash—Prednisolone—psoriasis	2.63e-05	0.000205	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—psoriasis	2.63e-05	0.00101	CbGpPWpGaD
Pimecrolimus—Dermatitis—Prednisolone—psoriasis	2.63e-05	0.000205	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.62e-05	0.000204	CcSEcCtD
Pimecrolimus—Headache—Prednisolone—psoriasis	2.61e-05	0.000204	CcSEcCtD
Pimecrolimus—MTOR—Immune System—HLA-E—psoriasis	2.61e-05	0.001	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—psoriasis	2.6e-05	0.001	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DRB1—psoriasis	2.59e-05	0.000998	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—psoriasis	2.59e-05	0.000998	CbGpPWpGaD
Pimecrolimus—Constipation—Prednisone—psoriasis	2.59e-05	0.000202	CcSEcCtD
Pimecrolimus—Vomiting—Hydrocortisone—psoriasis	2.59e-05	0.000202	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—STAT3—psoriasis	2.59e-05	0.000995	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NFKBIA—psoriasis	2.57e-05	0.00099	CbGpPWpGaD
Pimecrolimus—Rash—Hydrocortisone—psoriasis	2.57e-05	0.0002	CcSEcCtD
Pimecrolimus—Dermatitis—Hydrocortisone—psoriasis	2.57e-05	0.0002	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—CCL20—psoriasis	2.56e-05	0.000984	CbGpPWpGaD
Pimecrolimus—Headache—Hydrocortisone—psoriasis	2.55e-05	0.000199	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Methotrexate—psoriasis	2.53e-05	0.000197	CcSEcCtD
Pimecrolimus—Infection—Methotrexate—psoriasis	2.52e-05	0.000196	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—SOCS1—psoriasis	2.5e-05	0.000964	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ICAM1—psoriasis	2.49e-05	0.000958	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Methotrexate—psoriasis	2.48e-05	0.000193	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Prednisone—psoriasis	2.48e-05	0.000193	CcSEcCtD
Pimecrolimus—Nausea—Prednisolone—psoriasis	2.48e-05	0.000193	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—NFKBIA—psoriasis	2.47e-05	0.000951	CbGpPWpGaD
Pimecrolimus—Pruritus—Betamethasone—psoriasis	2.46e-05	0.000192	CcSEcCtD
Pimecrolimus—Pruritus—Dexamethasone—psoriasis	2.46e-05	0.000192	CcSEcCtD
Pimecrolimus—Skin disorder—Methotrexate—psoriasis	2.46e-05	0.000192	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—NOS2—psoriasis	2.46e-05	0.000946	CbGpPWpGaD
Pimecrolimus—Vomiting—Triamcinolone—psoriasis	2.44e-05	0.00019	CcSEcCtD
Pimecrolimus—Nausea—Hydrocortisone—psoriasis	2.42e-05	0.000188	CcSEcCtD
Pimecrolimus—Rash—Triamcinolone—psoriasis	2.42e-05	0.000188	CcSEcCtD
Pimecrolimus—Dermatitis—Triamcinolone—psoriasis	2.42e-05	0.000188	CcSEcCtD
Pimecrolimus—Urticaria—Prednisone—psoriasis	2.41e-05	0.000188	CcSEcCtD
Pimecrolimus—Headache—Triamcinolone—psoriasis	2.4e-05	0.000187	CcSEcCtD
Pimecrolimus—Body temperature increased—Prednisone—psoriasis	2.4e-05	0.000187	CcSEcCtD
Pimecrolimus—Abdominal pain—Prednisone—psoriasis	2.4e-05	0.000187	CcSEcCtD
Pimecrolimus—Diarrhoea—Betamethasone—psoriasis	2.38e-05	0.000185	CcSEcCtD
Pimecrolimus—Diarrhoea—Dexamethasone—psoriasis	2.38e-05	0.000185	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	2.35e-05	0.000904	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Methotrexate—psoriasis	2.31e-05	0.00018	CcSEcCtD
Pimecrolimus—Nausea—Triamcinolone—psoriasis	2.28e-05	0.000177	CcSEcCtD
Pimecrolimus—Paraesthesia—Methotrexate—psoriasis	2.27e-05	0.000177	CcSEcCtD
Pimecrolimus—Dyspnoea—Methotrexate—psoriasis	2.26e-05	0.000176	CcSEcCtD
Pimecrolimus—Hypersensitivity—Prednisone—psoriasis	2.23e-05	0.000174	CcSEcCtD
Pimecrolimus—Vomiting—Betamethasone—psoriasis	2.21e-05	0.000172	CcSEcCtD
Pimecrolimus—Vomiting—Dexamethasone—psoriasis	2.21e-05	0.000172	CcSEcCtD
Pimecrolimus—Rash—Dexamethasone—psoriasis	2.19e-05	0.000171	CcSEcCtD
Pimecrolimus—Rash—Betamethasone—psoriasis	2.19e-05	0.000171	CcSEcCtD
Pimecrolimus—Dermatitis—Betamethasone—psoriasis	2.19e-05	0.000171	CcSEcCtD
Pimecrolimus—Dermatitis—Dexamethasone—psoriasis	2.19e-05	0.000171	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Methotrexate—psoriasis	2.19e-05	0.00017	CcSEcCtD
Pimecrolimus—Headache—Dexamethasone—psoriasis	2.18e-05	0.00017	CcSEcCtD
Pimecrolimus—Headache—Betamethasone—psoriasis	2.18e-05	0.00017	CcSEcCtD
Pimecrolimus—MTOR—Immune System—SOCS1—psoriasis	2.18e-05	0.000838	CbGpPWpGaD
Pimecrolimus—Pain—Methotrexate—psoriasis	2.17e-05	0.000169	CcSEcCtD
Pimecrolimus—Pruritus—Prednisone—psoriasis	2.14e-05	0.000167	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—TYK2—psoriasis	2.11e-05	0.000811	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—psoriasis	2.1e-05	0.00081	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Prednisone—psoriasis	2.07e-05	0.000162	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methotrexate—psoriasis	2.07e-05	0.000161	CcSEcCtD
Pimecrolimus—Nausea—Betamethasone—psoriasis	2.07e-05	0.000161	CcSEcCtD
Pimecrolimus—Nausea—Dexamethasone—psoriasis	2.07e-05	0.000161	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—TYK2—psoriasis	2.01e-05	0.000775	CbGpPWpGaD
Pimecrolimus—Urticaria—Methotrexate—psoriasis	2.01e-05	0.000157	CcSEcCtD
Pimecrolimus—Abdominal pain—Methotrexate—psoriasis	2e-05	0.000156	CcSEcCtD
Pimecrolimus—Body temperature increased—Methotrexate—psoriasis	2e-05	0.000156	CcSEcCtD
Pimecrolimus—MTOR—Immune System—CD8A—psoriasis	1.93e-05	0.000744	CbGpPWpGaD
Pimecrolimus—Vomiting—Prednisone—psoriasis	1.93e-05	0.00015	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—psoriasis	1.93e-05	0.000741	CbGpPWpGaD
Pimecrolimus—Rash—Prednisone—psoriasis	1.91e-05	0.000149	CcSEcCtD
Pimecrolimus—Dermatitis—Prednisone—psoriasis	1.91e-05	0.000149	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—CD4—psoriasis	1.91e-05	0.000733	CbGpPWpGaD
Pimecrolimus—Headache—Prednisone—psoriasis	1.9e-05	0.000148	CcSEcCtD
Pimecrolimus—Hypersensitivity—Methotrexate—psoriasis	1.87e-05	0.000145	CcSEcCtD
Pimecrolimus—MTOR—Immune System—HLA-B—psoriasis	1.86e-05	0.000715	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—LEP—psoriasis	1.85e-05	0.000711	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APOE—psoriasis	1.85e-05	0.000711	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD4—psoriasis	1.83e-05	0.000704	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD4—psoriasis	1.82e-05	0.000701	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—psoriasis	1.81e-05	0.000695	CbGpPWpGaD
Pimecrolimus—Nausea—Prednisone—psoriasis	1.8e-05	0.00014	CcSEcCtD
Pimecrolimus—Pruritus—Methotrexate—psoriasis	1.79e-05	0.00014	CcSEcCtD
Pimecrolimus—Diarrhoea—Methotrexate—psoriasis	1.73e-05	0.000135	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—NFKBIA—psoriasis	1.72e-05	0.000663	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-A—psoriasis	1.72e-05	0.000663	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—JUN—psoriasis	1.71e-05	0.000656	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NDUFA5—psoriasis	1.66e-05	0.000639	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CRP—psoriasis	1.64e-05	0.000632	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NFKB1—psoriasis	1.64e-05	0.000632	CbGpPWpGaD
Pimecrolimus—Vomiting—Methotrexate—psoriasis	1.61e-05	0.000125	CcSEcCtD
Pimecrolimus—Rash—Methotrexate—psoriasis	1.6e-05	0.000124	CcSEcCtD
Pimecrolimus—Dermatitis—Methotrexate—psoriasis	1.6e-05	0.000124	CcSEcCtD
Pimecrolimus—MTOR—Disease—HLA-A—psoriasis	1.59e-05	0.000612	CbGpPWpGaD
Pimecrolimus—Headache—Methotrexate—psoriasis	1.59e-05	0.000124	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—NFKB1—psoriasis	1.58e-05	0.000607	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DRB1—psoriasis	1.57e-05	0.000605	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ICAM1—psoriasis	1.51e-05	0.000581	CbGpPWpGaD
Pimecrolimus—Nausea—Methotrexate—psoriasis	1.5e-05	0.000117	CcSEcCtD
Pimecrolimus—MTOR—Immune System—NFKBIA—psoriasis	1.5e-05	0.000577	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOE—psoriasis	1.48e-05	0.000571	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2S1—psoriasis	1.41e-05	0.000544	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TYK2—psoriasis	1.41e-05	0.000543	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—psoriasis	1.41e-05	0.000543	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SOCS1—psoriasis	1.41e-05	0.000542	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS2—psoriasis	1.38e-05	0.000532	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—psoriasis	1.23e-05	0.000473	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TYK2—psoriasis	1.23e-05	0.000472	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—psoriasis	1.15e-05	0.000442	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—JUN—psoriasis	1.14e-05	0.000439	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TYK2—psoriasis	1.13e-05	0.000436	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—psoriasis	1.11e-05	0.000427	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NFKB1—psoriasis	1.1e-05	0.000423	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LEP—psoriasis	1.04e-05	0.0004	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOE—psoriasis	1.04e-05	0.0004	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—psoriasis	1.03e-05	0.000397	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—psoriasis	1.02e-05	0.000394	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—psoriasis	9.98e-06	0.000384	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—JUN—psoriasis	9.93e-06	0.000382	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—psoriasis	9.88e-06	0.00038	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—psoriasis	9.85e-06	0.000379	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NFKBIA—psoriasis	9.69e-06	0.000373	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NFKB1—psoriasis	9.56e-06	0.000368	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—psoriasis	8.59e-06	0.000331	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TYK2—psoriasis	7.93e-06	0.000305	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—psoriasis	7.93e-06	0.000305	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—psoriasis	7.54e-06	0.00029	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—psoriasis	6.91e-06	0.000266	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—psoriasis	6.9e-06	0.000265	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CARM1—psoriasis	6.9e-06	0.000265	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JUN—psoriasis	6.42e-06	0.000247	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NFKB1—psoriasis	6.18e-06	0.000238	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—psoriasis	6e-06	0.000231	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—psoriasis	5.61e-06	0.000216	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—psoriasis	5.56e-06	0.000214	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—psoriasis	5.54e-06	0.000213	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAT—psoriasis	4.24e-06	0.000163	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—psoriasis	4.24e-06	0.000163	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—psoriasis	3.88e-06	0.000149	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOE—psoriasis	3.3e-06	0.000127	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARG—psoriasis	2.87e-06	0.000111	CbGpPWpGaD
